Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMMB Chemomab Therapeutics	$0.87 -2.3%	$1.09	$0.83 ▼ $2.55	$16.41M	0.52	226,179 shs	268,122 shs
COCP Cocrystal Pharma	$1.53 -2.3%	$1.61	$1.12 ▼ $3.26	$15.71M	2.07	42,372 shs	28,317 shs
GTBP GT Biopharma	$1.09 -1.8%	$2.23	$0.96 ▼ $4.10	$3.88M	1.33	255,302 shs	99,741 shs
SYBX Synlogic	$1.48 +1.4%	$1.38	$0.90 ▼ $1.96	$17.32M	0.52	26,747 shs	35,515 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMMB Chemomab Therapeutics	0.00%	-4.30%	-18.35%	-34.80%	-36.43%
COCP Cocrystal Pharma	0.00%	-7.67%	-2.25%	+7.19%	-20.96%
GTBP GT Biopharma	0.00%	-17.16%	-46.12%	-61.59%	-48.85%
SYBX Synlogic	0.00%	-1.35%	-8.18%	+29.20%	-2.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMMB Chemomab Therapeutics	3.3303 of 5 stars	3.5	5.0	0.0	0.0	2.6	1.7	0.6
COCP Cocrystal Pharma	2.8588 of 5 stars	3.5	5.0	0.0	0.0	2.0	1.7	0.0
GTBP GT Biopharma	1.7685 of 5 stars	3.8	2.0	0.0	0.0	1.1	0.0	0.6
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMMB Chemomab Therapeutics	3.00	Buy	$8.50	877.12% Upside
COCP Cocrystal Pharma	3.00	Buy	$6.00	291.90% Upside
GTBP GT Biopharma	3.50	Strong Buy	$11.00	909.17% Upside
SYBX Synlogic	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GTBP, CMMB, COCP, and SYBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/20/2025	COCP Cocrystal Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.94 per share	N/A
GTBP GT Biopharma	N/A	N/A	N/A	N/A	($0.75) per share	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	$1.09 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMMB Chemomab Therapeutics	-$13.94M	-$0.59	N/A	N/A	N/A	N/A	-94.71%	-76.53%	11/13/2025 (Estimated)
COCP Cocrystal Pharma	-$17.50M	-$1.24	N/A	N/A	N/A	N/A	-144.12%	-102.85%	11/12/2025 (Estimated)
GTBP GT Biopharma	-$13.16M	-$4.07	N/A	N/A	N/A	N/A	-1,804.34%	-200.12%	11/13/2025 (Estimated)
SYBX Synlogic	-$23.36M	-$2.51	N/A	N/A	N/A	N/A	-8.09%	-5.50%	11/11/2025 (Estimated)

Latest GTBP, CMMB, COCP, and SYBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CMMB Chemomab Therapeutics	-$0.20	-$0.09	+$0.11	-$0.09	N/A	N/A
8/14/2025	Q2 2025	COCP Cocrystal Pharma	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
8/14/2025	Q2 2025	GTBP GT Biopharma	-$0.68	-$0.55	+$0.13	-$0.55	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
GTBP GT Biopharma	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMMB Chemomab Therapeutics	N/A	7.42	7.42
COCP Cocrystal Pharma	N/A	3.69	3.69
GTBP GT Biopharma	N/A	2.76	2.76
SYBX Synlogic	N/A	3.63	3.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMMB Chemomab Therapeutics	46.05%
COCP Cocrystal Pharma	6.72%
GTBP GT Biopharma	8.15%
SYBX Synlogic	63.40%

Insider Ownership

Company	Insider Ownership
CMMB Chemomab Therapeutics	11.91%
COCP Cocrystal Pharma	28.14%
GTBP GT Biopharma	3.40%
SYBX Synlogic	3.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMMB Chemomab Therapeutics	20	18.86 million	16.61 million	Not Optionable
COCP Cocrystal Pharma	10	10.26 million	7.37 million	Not Optionable
GTBP GT Biopharma	8	3.56 million	3.44 million	No Data
SYBX Synlogic	80	11.70 million	11.35 million	Optionable

GTBP, CMMB, COCP, and SYBX Headlines

Recent News About These Companies

Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Synlogic's executive sells shares worth $2,802

February 5, 2025 | msn.com

Synlogic Reports Q3 2024 Financial Outcomes

November 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results

November 13, 2024 | finanznachrichten.de

Synlogic Reports Third Quarter 2024 Financial Results

November 12, 2024 | globenewswire.com

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

November 6, 2024 | pharmaphorum.comP

Synlogic, Inc. (0A8U.L)

August 24, 2024 | nz.finance.yahoo.com

MIN.SG,0P0001I7V6,0 (MIN.SG)

August 16, 2024 | nz.finance.yahoo.com

Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty

August 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | finanznachrichten.de

SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024

August 8, 2024 | investorplace.com

Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | globenewswire.com

Synlogic Inc.

July 21, 2024 | wsj.com

Synlogic Inc SYBX

July 21, 2024 | morningstar.comM

The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits

May 23, 2024 | investorplace.com

Hold Rating Maintained for Synlogic Amidst Setbacks and Financial Uncertainties

May 16, 2024 | markets.businessinsider.com

SYBX Stock Earnings: Synlogic Misses EPS, Misses Revenue for Q1 2024

May 14, 2024 | investorplace.com

Synlogic, Inc.: Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | finanznachrichten.de

Synlogic Flat on Q1 Numbers

May 14, 2024 | baystreet.ca

Synlogic Reports First Quarter 2024 Financial Results

May 14, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP, CMMB, COCP, and SYBX Company Descriptions

Chemomab Therapeutics NASDAQ:CMMB

$0.87 -0.02 (-2.26%)

Closing price 03:59 PM Eastern

Extended Trading

$0.88 +0.01 (+1.16%)

As of 05:52 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Cocrystal Pharma NASDAQ:COCP

$1.53 -0.04 (-2.26%)

Closing price 03:58 PM Eastern

Extended Trading

$1.54 +0.01 (+0.52%)

As of 04:01 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

GT Biopharma NASDAQ:GTBP

$1.09 -0.02 (-1.80%)

Closing price 03:50 PM Eastern

Extended Trading

$1.10 +0.01 (+0.92%)

As of 05:01 PM Eastern

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Synlogic NASDAQ:SYBX

$1.48 +0.02 (+1.03%)

As of 04:00 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time